CSRxP COMMENDS PRESIDENT BIDEN FOR RENEWED COMMITMENT TO HOLDING BIG PHARMA ACCOUNTABLE

Campaign Looks Forward to Working with Administration and Congress to Crack Down on Anti-Competitive Practices and Lower Rx Price

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Friday in response to executive order and comments from President Biden encouraging increased federal action to lower drug prices and hold Big Pharma accountable.

“CSRxP commends President Biden for renewing his administration’s commitment to holding Big Pharma accountable and for recognizing the importance of boosting competition,” said CSRxP executive director Lauren Aronson. “CSRxP looks forward to working with the administration and Congress on long term structural reforms to lower drug prices and crack down on Big Pharma’s egregious anti-competitive and price-hiking practices.”

In May, the President called on Congress to lower prescription drug prices as part of his administration’s Fiscal Year 2022 Budget. During a Joint Address to Congress in April, the President also called for lawmakers to work in which he also called for bipartisan solutions to lower prescription drug prices.

Big Pharma is actively engaged in a third major round of price hikes on branded prescription drugs since the start of the COVID-19 pandemic. As of Friday, drug companies have increased prices on 57 brand name medicationsthis month.

Learn more on market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.